TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25042846

Group type: EXPERIMENTAL
Intervention: yogurt
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3300 FCC units acid lactase from Aspergillus oryzae
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 9000 FCC units acid lactase from Aspergillus oryzae
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3300 FCC units lactase plus yogurt culture combined
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 25026747

Group type: EXPERIMENTAL
Intervention: Dermatological patients
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Patients after first heart attack
Number of subjects: 480

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 480
Study: 21474838

Group type: EXPERIMENTAL
Intervention: Dietary intervention aimed at restricting saturated fat and cholesterol intake
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group with no special recommendations
Number of subjects: 86
Study: 19463377

Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg/day
Number of subjects: 153

Group type: COMPARATOR
Intervention: Clopidogrel 150 mg/day after switching from 75 mg/day
Number of subjects: 153

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/day
Number of subjects: 153
Study: 16509522

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IGF-I
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Multiple regression model with head circumference as dependent variable
Number of subjects: 36
Study: 14984519

Group type: EXPERIMENTAL
Intervention: Indomethacin (bolus of 0.2 mg.kg‐1 followed by an infusion of 0.2 mg.kg‐1.h‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Indomethacin and Placebo
Number of subjects: 30
Study: 11107461

Group type: EXPERIMENTAL
Intervention: 1998 Canadian lipid guidelines
Number of subjects: 5900000

Group type: EXPERIMENTAL
Intervention: Framingham risk equations
Number of subjects: 5900000

Group type: COMPARATOR
Intervention: Risk counting
Number of subjects: 5900000
Study: 9077498

Group type: EXPERIMENTAL
Intervention: SMA II (n=240)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: SMA III (n=329)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: SMA IIIa (n=195)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: SMA IIIb (n=134)
Number of subjects: 569
Study: 8482443

Group type: EXPERIMENTAL
Intervention: 4 g/day mesalamine
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: 4 g/day mesalamine (in patients with ileum-only disease)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo (in patients with ileum-only disease)
Number of subjects: 310
Study: 3156614

Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg kg‐1 i.m.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam 0.2 mg kg‐1 i.m.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30852971

Group type: EXPERIMENTAL
Intervention: Aspirin plus Clopidogrel (A+C) therapy (short-term, ≤1 month)
Number of subjects: 15434

Group type: EXPERIMENTAL
Intervention: Aspirin plus Clopidogrel (A+C) therapy (intermediate-term, ≤3 months)
Number of subjects: 15434

Group type: EXPERIMENTAL
Intervention: Aspirin plus Clopidogrel (A+C) therapy (long-term, >3 months)
Number of subjects: 15434

Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 15434
Study: 29229354

Group type: EXPERIMENTAL
Intervention: Tac OD
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tac BID
Number of subjects: 45

Group type: COMPARATOR
Intervention: Tac OD and Tac BID
Number of subjects: 45
Study: 27616162

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) for 8 weeks, 3 times a week, 8 whole-body exercises, 3 sets of 10-15 repetition maximum (RM)
Number of subjects: 38
Study: 24533897

Group type: EXPERIMENTAL
Intervention: Complex behavioural intervention (diet with lower glycemic index and physical activity)
Number of subjects: 1546

Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 1546
Study: 22697367

Group type: EXPERIMENTAL
Intervention: Shaoyang specific acupuncture
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Shaoyang non-specific acupuncture
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Yangming specific acupuncture
Number of subjects: 480

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 480
Study: 19674876

Group type: EXPERIMENTAL
Intervention: Investigational antihypertensive drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17525838

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional surgical methods
Number of subjects: 0
Study: 15585539

Group type: EXPERIMENTAL
Intervention: Brief physiotherapy intervention (1-3 sessions using cognitive behaviour principles)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 268
Study: 11863327

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 1729
Study: 10029616

Group type: EXPERIMENTAL
Intervention: Clonidine (0.0125, 0.025, or 0.1 mg orally)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.3 or 0.5 microgram.kg‐1.min‐1 intravenous)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Clonidine and placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combined nitroglycerin plus clonidine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 7779232

Group type: EXPERIMENTAL
Intervention: Standardized performance-based criteria for support surfaces
Number of subjects: 0
Study: 2144266

Group type: EXPERIMENTAL
Intervention: Use of large data bases in technology assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Major approaches to technology assessment
Number of subjects: 0
Study: 468444

Group type: EXPERIMENTAL
Intervention: 2.8% THC inhalation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30377019

Group type: EXPERIMENTAL
Intervention: En bloc technique
Number of subjects: 53

Group type: COMPARATOR
Intervention: Branched graft technique
Number of subjects: 53
Study: 29850961

Group type: EXPERIMENTAL
Intervention: 8 J/cm2
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 60 J/cm2
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 105 J/cm2
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study: 24858914

Group type: EXPERIMENTAL
Intervention: Wearing personal protective equipment (PPE) during airway management
Number of subjects: 40

Group type: COMPARATOR
Intervention: Not wearing personal protective equipment (PPE) during airway management
Number of subjects: 40
Study: 25091346

Group type: EXPERIMENTAL
Intervention: Psyllogel Megafermenti(®) 2 bags/day for 8 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Maltodextrin 2.8 g twice daily for 8 weeks
Number of subjects: 29
Study: 23111651

Group type: EXPERIMENTAL
Intervention: Ergocalciferol, 50,000 units, orally once a week for 8 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ergocalciferol and Placebo
Number of subjects: 12
Study: 19294365

Group type: EXPERIMENTAL
Intervention: Heated humidifiers (HH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bubble humidifiers (BH)
Number of subjects: 30
Study: 17446567

Group type: EXPERIMENTAL
Intervention: Parental substance use disorders
Number of subjects: 0

Group type: COMPARATOR
Intervention: CWS and substance abuse treatment systems
Number of subjects: 0
Study: 15106850

Group type: EXPERIMENTAL
Intervention: EMF exposure before testing session
Number of subjects: 0

Group type: COMPARATOR
Intervention: EMF exposure during data collecting session
Number of subjects: 0
Study: 12044508

Group type: EXPERIMENTAL
Intervention: Gemcitabine-radiotherapy (gemcitabine at 300 mg/m² concurrent with radiotherapy, three fractions of 8 Gy on days 1, 8, and 15; followed by gemcitabine alone at 1000 mg/m² weekly for 3 weeks every 4 weeks if compliance allowed)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Non-haematological toxicity
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Surgical resection post-chemoradiation
Number of subjects: 24
Study: 9527088

Group type: EXPERIMENTAL
Intervention: Alcohol, 1 g/kg body weight, mixed with 500 ml of juice
Number of subjects: 9

Group type: COMPARATOR
Intervention: Alcohol, 1 g/kg body weight, mixed with 500 ml of juice plus 750 ml of mineral water
Number of subjects: 9
Study: 7610803

Group type: COMPARATOR
Intervention: No otitis media episodes until 2 years of age (healthy children)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Recurrent acute otitis media (RAOM; > or = 4 episodes)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Secretory otitis media (SOM)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: History of otitis media (RAOM or SOM)
Number of subjects: 266
Study: 2231218

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 9
Study: 881098

Group type: EXPERIMENTAL
Intervention: Slow aspirin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Plain aspirin
Number of subjects: 18
Study: 31605461

Group type: EXPERIMENTAL
Intervention: Urinary angiotensinogen (uAOG)
Number of subjects: 0
Study: 28093483

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir + lamivudine (300 mg atazanavir/100 mg ritonavir once daily and 300 mg lamivudine once daily)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Atazanavir/ritonavir + two NRTIs
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir + lamivudine
Number of subjects: 266
Study: 25814381

Group type: EXPERIMENTAL
Intervention: Medication-assisted therapy (buprenorphine or methadone)
Number of subjects: 1039
Study: 23870611

Group type: EXPERIMENTAL
Intervention: Sarpogrelate CR 300 mg administered in the fasted condition
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sarpogrelate CR 300 mg administered after a high-fat breakfast
Number of subjects: 24
Study: 22201239

Group type: EXPERIMENTAL
Intervention: Multimedia SiHLE intervention
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 178
Study: 19258984

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided perivascular sural nerve block (group US) with 5 mL of 3% chloroprocaine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional landmark-based sural nerve block (group TRAD) with 5 mL of 3% chloroprocaine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided perivascular sural nerve block (group US)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional landmark-based sural nerve block (group TRAD)
Number of subjects: 18
Study: 16960779

Group type: EXPERIMENTAL
Intervention: HIV-1 infected patients with CD4 <300 cells/microL
Number of subjects: 971

Group type: COMPARATOR
Intervention: HIV-1 infection
Number of subjects: 971
Study: 14722635

Group type: EXPERIMENTAL
Intervention: Protective tidal volumes (6 ml/kg, respiratory rate: 15 breaths/min, PEEP 5 cmH(2)O, n=15)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional tidal volumes with PEEP (10 ml/kg, respiratory rate: 9 breaths/min, PEEP 5 cmH(2)O, n=14)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional tidal volumes without PEEP (10 ml/kg, respiratory rate: 9 breaths/min, n=15)
Number of subjects: 44
Study: 14632857

Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 0
Study: 10193959

Group type: EXPERIMENTAL
Intervention: 950 microsec pulsed CO2 laser with 3 passes at 300 mJ followed by Er:YAG laser with 2 passes at 1.7 J
Number of subjects: 10

Group type: COMPARATOR
Intervention: 950 microsec pulsed CO2 laser with 2 passes at 300 mJ
Number of subjects: 10
Study: 7579511

Group type: EXPERIMENTAL
Intervention: Positive immunostaining for heat-shock protein-27 (HSP-27) using a polyclonal antibody (Hu27, dilution: 1/200)
Number of subjects: 890

Group type: COMPARATOR
Intervention: Negative immunostaining for heat-shock protein-27 (HSP-27)
Number of subjects: 890
Study: 2158487

Group type: EXPERIMENTAL
Intervention: Combined therapy (intralesional stibogluconate injection and superficial cryotherapy)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Superficial cryotherapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intralesional stibogluconate injection alone
Number of subjects: 15
Study: 6153721

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Ampicillin with probenecid
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Sulphonamide vaginal tablets
Number of subjects: 582

Group type: COMPARATOR
Intervention: Direct microscopy
Number of subjects: 582
Study: 31113481

Group type: EXPERIMENTAL
Intervention: Negative pressure wound dressings (NPD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Static pressure dressings (SPD)
Number of subjects: 24
Study: 28851451

Group type: EXPERIMENTAL
Intervention: 2-week exercise program with four 20-min exercise sessions on 3 days per week
Number of subjects: 85

Group type: COMPARATOR
Intervention: Social stimulation program (Control Group)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Antipsychotic and sedative dosage quantified by olanzapine and diazepam equivalents
Number of subjects: 85
Study: 25817183

Group type: EXPERIMENTAL
Intervention: Intra-articular 3g TXA plus 0.25mg DEP (1:200,000)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Topical 3g TXA alone
Number of subjects: 100
Study: 23968817

Group type: EXPERIMENTAL
Intervention: Pre-knee arthroplasty
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Post-knee arthroplasty
Number of subjects: 54

Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sit-stand activity
Number of subjects: 54
Study: 21047567

Group type: EXPERIMENTAL
Intervention: Beta-blockers (BB)
Number of subjects: 3488
Study: 19586227

Group type: EXPERIMENTAL
Intervention: CRA plus low monetary value vouchers (0.125 Euro, US$ 0.18)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CRA plus high monetary value vouchers (0.25 Euro, US$ 0.36)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard outpatient treatment
Number of subjects: 96
Study: 17149647

Group type: EXPERIMENTAL
Intervention: Brace free accelerated rehabilitation (group B)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard post-operative rehabilitation (group A)
Number of subjects: 45
Study: 15055894

Group type: EXPERIMENTAL
Intervention: Eutectic mixture of local anaesthetic cream (EMLA) applied for 60 min followed by sham iontophoresis
Number of subjects: 28

Group type: COMPARATOR
Intervention: Lidocaine iontophoresis (2 mA for 10 min with lidocaine 4% and epinephrine 1 in 50,000)
Number of subjects: 28
Study: 11176086

Group type: EXPERIMENTAL
Intervention: 10 microg sufentanil
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 5 mg bupivacaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2.5 microg sufentanil plus 2.5 mg bupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 80
Study: 9644411

Group type: EXPERIMENTAL
Intervention: Teen FreshStart with a buddy program (TFSB)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Teen FreshStart program (TFS) without peer support
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 46
Study: 7935523

Group type: EXPERIMENTAL
Intervention: Intermittent, progressive, isometric contractions of the ankle dorsiflexors
Number of subjects: 14
Study: 31608653

Group type: EXPERIMENTAL
Intervention: Automated irrigation pump (AIP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Manual hand pump (HP)
Number of subjects: 80
Study: 30335610

Group type: EXPERIMENTAL
Intervention: Neutral Spinal Bath (NSB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neutral Spinal Spray (NSS)
Number of subjects: 30
Study: 26868965

Group type: EXPERIMENTAL
Intervention: Direct technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indirect technique
Number of subjects: 0
Study: 24979615

Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Mixed diet
Number of subjects: 8
Study: 22261004

Group type: EXPERIMENTAL
Intervention: Lidocaine (2mg/kg plus 50 μg/kg/min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Buprenorphine without lidocaine (BC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fentanyl without lidocaine (FC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Buprenorphine and lidocaine (BL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fentanyl and lidocaine (FL)
Number of subjects: 24
Study: 20171455

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) and subsequent intervention including medication adjustment, exercise instruction, nutrition support, physical rehabilitation, social worker consultation, and specialty referral.
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 310
Study: 18833146

Group type: EXPERIMENTAL
Intervention: Cryosupernatant plasma (CSNP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fresh frozen plasma
Number of subjects: 60
Study: 16625443

Group type: EXPERIMENTAL
Intervention: Regensburg ambulation aid
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (ambulation training discontinued for at least 6 weeks)
Number of subjects: 10
Study: 14503013

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other lipid lowering agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-users of lipid-lowering agents)
Number of subjects: 0
Study: 10789718

Group type: EXPERIMENTAL
Intervention: Paclitaxel 80 mg m(‐2) over 3 h and nolatrexed 500 mg m(‐2) day(‐1) as a 120‐h continuous intravenous infusion (Schedule 1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Paclitaxel 80 mg m(‐2) over 3 h and nolatrexed 500 mg m(‐2) day(‐1) as a 120‐h continuous intravenous infusion (Schedule 2)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Paclitaxel 80 mg m(‐2) over 3 h and nolatrexed 500 mg m(‐2) day(‐1) as a 120‐h continuous intravenous infusion (Schedule 3)
Number of subjects: 9
Study: 8969572

Group type: EXPERIMENTAL
Intervention: Verapamil COER‐24 240 mg at 10 PM
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 1485477

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (400 mg for 7 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: NaCl (control)
Number of subjects: 30
Study: 3901374

Group type: EXPERIMENTAL
Intervention: GoLYTELY (polyethylene glycol-electrolyte lavage solution)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Traditional 3-day bowel preparation
Number of subjects: 53
Study: 30558818

Group type: EXPERIMENTAL
Intervention: Quadrivalent inactivated influenza vaccine (IIV4), two full doses 28 days apart.
Number of subjects: 5806

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5806

Group type: COMPARATOR
Intervention: Licensed trivalent split-virion inactivated vaccine (IIV3)
Number of subjects: 5806

Group type: COMPARATOR
Intervention: Investigational IIV3 containing a B strain from the alternate lineage
Number of subjects: 5806
Study: 29487335

Group type: EXPERIMENTAL
Intervention: Female subjects exhibiting exhibitionistic, frotteuristic, sexual sadistic, and pedophilic behavior
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Female subjects fulfilling diagnostic criteria for masochistic disorder
Number of subjects: 546

Group type: COMPARATOR
Intervention: Control condition with psychotic symptoms
Number of subjects: 546
Study: 26474116

Group type: EXPERIMENTAL
Intervention: Fall risk assessment intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Care-as-usual group
Number of subjects: 150
Study: 24949544

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation (9 doses of 50,000 IU of cholecalciferol over 24 weeks)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (matching placebo for vitamin D)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 21620465

Group type: EXPERIMENTAL
Intervention: Gum chewing (GC) during class and testing
Number of subjects: 108

Group type: COMPARATOR
Intervention: No gum chewing (NGC)
Number of subjects: 108
Study: 19880855

Group type: EXPERIMENTAL
Intervention: Depressed LVEF (case group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Normal LVEF (control group)
Number of subjects: 72
Study: 17272618

Group type: EXPERIMENTAL
Intervention: Betamethasone (12 mg)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 16240958

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus Total‐Etch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus Self‐Etch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 11890845

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 10
Study: 9866000

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 micrograms every 3 h for a maximum of five doses in 24 h)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Vaginal gemeprost (1 mg every 3 h for a maximum of five doses in 24 h)
Number of subjects: 140
Study: 9097753

Group type: EXPERIMENTAL
Intervention: Nimodipine (oral administration, acute dose)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 2771438

Group type: EXPERIMENTAL
Intervention: Continuous epidural bupivacaine infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular narcotic analgesia
Number of subjects: 0
Study: 340134

Group type: EXPERIMENTAL
Intervention: Tinidazole (single oral dose of 50 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metronidazole (single oral dose of 50 mg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 100
Study: 31144240

Group type: EXPERIMENTAL
Intervention: Probucol (10 Âµmol/L) in hyperglycemia (30 mmol/L)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Hyperglycemia (30 mmol/L)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Normoglycemia (5.5 mmol/L)
Number of subjects: 3